ERBB2 and breast cancer: Moreover, antibody‐based treatments directed against surface HER2, an antigen overexpressed in about 15–30% of breast cancers,3, 4, 5, 6 are limited by resistance mechanisms including the expression of truncated HER2 variants and shedding of the HER2 ectodomain.7